NCT07726355CompletedPhase 2/3
A Randomized Clinical Trial Evaluating the Efficacy of Clinical Pharmacist Assistance Along With Pharmaceutical and Non-pharmaceutical Therapy in the Early Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
Background: Rheumatoid arthritis (RA) is a progressive chronic autoimmune disease with a rising global burden, in which early diagnosis and timely therapeutic intervention are critical to preventing irreversible joint damage and preserving long-term function. Despite established treat-to-target (T2T) frameworks-incorporating conventional, biological, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) and endorsed by the European Alliance of Associations for Rheumatology (EULAR) and the American College of Rheumatology (ACR)-a substantial proportion of patients with early RA fail to achieve the recommended target of DAS28 \<2.6 (remission) or 2.6-3.2 (low disease activity), reflecting persistent gaps in disease management. Pharmacological therapy alone is insufficient: adherence barriers, inadequate disease knowledge, psychosocial distress, unresolved medication-related problems, and suboptimal monitoring continue to undermine outcomes. Clinical pharmacists, whose scope of practice has expanded substantially beyond dispensing to encompass medication optimization, patient education, and behavioral support, represent an underutilized resource in rheumatology care. Purpose: This narrative review synthesizes available evidence on the impact of clinical pharmacist-led interventions on disease activity (DAS28), medication adherence, functional disability, and quality of life (QoL) outcomes in patients with early RA, with particular attention to non-pharmacological mechanisms of effect and the role of adherence as a core mediating outcome.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 70 (actual)
- First submitted
- 19 Jul 2026
- Start date
- Apr 2025
- Primary completion date
- May 2026
- Lead sponsor
- Deraya University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07726355
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 70
- From Apr 2025 to the primary completion date, May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of oral glucocorticoids \>10 mg/day during the previous 3 weeks.
- Current biological DMARD therapy.
Other illness
- Active infection.
- Malignancy.
- Other autoimmune or musculoskeletal disorders.
Lab values
- AST or ALT \>3 times the upper limit of normal.
- eGFR \<30 mL/min/1.73 m².
Other
- Pregnancy or lactation.
- Inability to participate in follow-up.
Who the study is looking for
- Adult patients aged 18-65 years.
- Diagnosis of early RA according to the 2010 ACR/EULAR classification criteria.
- Disease lasts less than 2 years.
- Presence of at least one tender and one swollen joint.
- Ability to provide informed consent.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assiut university Coordinator of this site? Confirm its status | Minya | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.